Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469

Barclays analyst Andrew Mok has maintained an Overweight rating on Elevance Health (NYSE: ELV) and increased the price target from $457 to $469. This adjustment reflects a positive outlook for the company in the market.